Literature DB >> 11429704

Functional characterization of naturally occurring mutants (P405R and P425L) of p73alpha and p73beta found in neuroblastoma and lung cancer.

M Naka1, T Ozaki, N Takada, M Takahashi, T Shishikura, S Sakiyama, M Tada, S Todo, A Nakagawara.   

Abstract

The novel candidate tumor suppressor p73, a structural and functional homolog of p53, activates various p53 responsive promoters and induces tumor cell apoptosis. Although p73 is infrequently mutated in human cancers, we have previously found two types of p73 mutation with amino acid substitution (P405R and P425L) in primary neuroblastoma and lung cancer. Here we report generations of the p73 mutants with either P405R or P425L substitution and functional analysis of these naturally occurring mutants. Indirect immunofluorescence staining revealed that nuclear accumulation of p73alpha or p73beta was not affected by these mutations. The P425L substitution reduced the ability of p73alpha to transactivate various p53 responsive promoters (p21(Waf1), Mdm2, and Bax). Moreover, this down-regulation was correlated with the reduced capability of p73alpha(P425L) to suppress cell growth in p53-deficient SAOS-2 cells. In contrast, p73beta(P425L) was as effective as wild-type p73beta in transactivation and growth inhibition. On the other hand, the P405R substitution had no significant effect on both the transcriptional activity and the growth-suppressive ability of p73alpha or p73beta. These results suggested that, at least, one of the naturally occurring p73 mutants, p73alpha(P425L), was a functionally defective mutant of p73.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11429704     DOI: 10.1038/sj.onc.1204470

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  Protein kinase C-dependent phosphorylation regulates the cell cycle-inhibitory function of the p73 carboxy terminus transactivation domain.

Authors:  Ulrika Nyman; Pinelopi Vlachos; Anna Cascante; Ola Hermanson; Boris Zhivotovsky; Bertrand Joseph
Journal:  Mol Cell Biol       Date:  2009-01-21       Impact factor: 4.272

2.  Epigenetic modification in the expression of p73 p73 - epigenetic target for anticancer therapy.

Authors:  Faiza Naseer; Mohammad Saleem
Journal:  Oncol Rev       Date:  2019-07-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.